Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.47 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 5/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776036 | 0.90 | NAMPT (0.44) | CCR1NAMPTLIPECYP51A1 | |
| SCHEMBL2773480 | 0.89 | NAMPT (0.47) | CCR1NAMPTMMP1LIPE | |
| SCHEMBL2776415 | 0.89 | LIPE (0.53) | CCR1NAMPTLIPE | |
| SCHEMBL2774490 | 0.88 | CCR1 (0.52) | CCR1NAMPT | |
| SCHEMBL2774622 | 0.88 | MMP1 (0.49) | CCR1NAMPTMMP1 | |
| SCHEMBL2776026 | 0.87 | NAMPT (0.42) | CCR1NAMPTMMP1LIPE | |
| SCHEMBL2775343 | 0.87 | CCR1 (0.47) | CCR1NAMPTMMP1LIPE | |
| SCHEMBL12977930 | 0.82 | NAMPT (0.43) | CCR1NAMPT | |
| SCHEMBL2777374 | 0.81 | LMNA (0.44) | CCR1CYP51A1 | |
| SCHEMBL2773777 | 0.81 | NAMPT (0.43) | CCR1NAMPTCYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CCR1 1428/4885NAMPT 1696/4885MMP1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.